For instance, IDH1 mutations occur in > 70% of low-grade gliomas (LGGs) [60], EGFR amplification appears in > 50% of glioblastomas (GBMs) [61], and TP53 is an independent prognostic marker for LGG, although its mechanism remains unclear [62]. Here, EGFR is linked to low grade glioma.